Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Schuller AG"'
Publikováno v:
FEBS Letters. 291:264-268
To define domains involved in IGF binding 60 N-terminal amino acid residues of IGFBP-1 were deleted. This deletion resulted in loss of IGF binding suggesting that the N-terminus may enclose an IGF binding domain. However, most point mutations introdu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f2f8ececc3db23894917171b4f83825
https://doi.org/10.1016/0014-5793(91)81298-m
https://doi.org/10.1016/0014-5793(91)81298-m
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mlynarski SN; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Aquila BM; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Cantin S; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Cook S; Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca, Waltham 02451, Massachusetts, United States., Doshi A; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Finlay MRV; Early Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gangl ET; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Grebe T; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Gu C; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Kawatkar SP; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Petersen J; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Mölndal SE-431 83, Sweden., Pop-Damkov P; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Schuller AG; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Shao W; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Shields JD; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Simpson I; Early Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Tavakoli S; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Mölndal SE-431 83, Sweden., Tentarelli S; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Throner S; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Wang H; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States., Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca, Waltham 02451, Massachusetts, United States., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca, Waltham 02451, Massachusetts, United States., Ye Q; Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Nov 21. Date of Electronic Publication: 2024 Nov 21.
Autor:
Graziano V; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK vincenzo.graziano@astrazeneca.com Duncan.Jodrell@cruk.cam.ac.uk.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK., Dannhorn A; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Hulme H; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Williamson K; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK., Buckley H; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Karim SA; Cancer Research UK Beatson Institute, Glasgow, UK., Wilson M; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Lee SY; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kaistha BP; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Islam S; Department of Oncology, University of Cambridge, Cambridge, UK., Thaventhiran JED; Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK., Richards FM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Goodwin R; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca R&D, Cambridge, UK., Brais R; Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Morton JP; Cancer Research UK Beatson Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Dovedi SJ; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Schuller AG; Oncology, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Eyles J; Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK., Jodrell DI; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK vincenzo.graziano@astrazeneca.com Duncan.Jodrell@cruk.cam.ac.uk.; Department of Oncology, University of Cambridge, Cambridge, UK.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Aug; Vol. 11 (8).
Autor:
Jones RDO; Oncology R&D, Research and Early Development, AstraZeneca, Cambridge, United Kingdom., Petersson K; qPharmetra LLC, Stockholm, Sweden., Tabatabai A; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts., Bao L; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts., Tomkinson H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Schuller AG; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 679-690.
Autor:
Doshi AS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hernandez M; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Srinivasan S; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tentarelli S; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Griffin M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wang Y; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pop-Damkov P; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Prickett LB; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Kankkonen C; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden., Shen M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Martin MS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wu S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Castaldi MP; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts., Ghadially H; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Varnes J; Global Portfolio and Project Management, Waltham, Massachusetts., Gales S; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Henry D; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Hoover C; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Mele DA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Simpson I; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Mlynarski SN; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Finlay MRV; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Shao W; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645.
Autor:
Vasalou C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Li W; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Muse V; Novo Nordisk Foundation Center for Protein Research, Copenhagen 2200, Denmark., Gibbons FD; Biogen, Cambridge, Massachusetts 02142, United States., Sonzini S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Zhang G; Dicerna Pharmaceuticals, Inc, Lexington, Massachusetts 02421, United States., Pop-Damkov P; Takeda Pharmaceuticals, Cambridge, Massachusetts 02139, United States., Gangl E; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Balachander SB; Bristol-Myers Squibb, Cambridge, Massachusetts 02142, United States., Wen S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Schuller AG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Puri S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Mazza M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Ashford M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Fretland AJ; Repare Therapeutics, Cambridge, Massachusetts 02142, United States., McGinnity DF; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Jones RDO; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.
Publikováno v:
Molecular pharmaceutics [Mol Pharm] 2022 Jan 03; Vol. 19 (1), pp. 172-187. Date of Electronic Publication: 2021 Dec 10.
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer.
Autor:
Eser PÖ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02115, USA., Paranal RM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Son J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Ivanova E; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kuang Y; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Okoro JJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dholakia KH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Choi J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Eum Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Missios P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA., Ercan D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xu M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Poitras MJ; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wang S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ngo K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dills M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Yanagita M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lopez T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lin M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Tsai J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Floch N; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Chambers ES; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Heng J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anjum R; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Santucci AD; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Michael K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Cross D; Global Medical Affairs, Oncology Business Unit, AstraZeneca, 136 Hills Road, Cambridge CB2 8PA, UK., Smith PD; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Oxnard GR; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Barbie DA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Palakurthi S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Daley GQ; Harvard Medical School, Boston, MA 02115, USA.; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Cambridge, MA 02138, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Publikováno v:
Science translational medicine [Sci Transl Med] 2021 Sep; Vol. 13 (609), pp. eabb3738. Date of Electronic Publication: 2021 Sep 01.
Autor:
Patterson CM; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Balachander SB; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Grant I; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK., Pop-Damkov P; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Kelly B; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., McCoull W; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Parker J; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Giannis M; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., Hill KJ; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK., Gibbons FD; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Hennessy EJ; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Kemmitt P; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Harmer AR; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Gales S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Purbrick S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Redmond S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, 02451, USA., Skinner M; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Graham L; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK., Secrist JP; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Schuller AG; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Wen S; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Adam A; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Reimer C; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Cidado J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Wild M; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Gangl E; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Fawell SE; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Saeh J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA., Davies BR; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK., Owen DJ; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia., Ashford MB; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. Marianne.Ashford@astrazeneca.com.
Publikováno v:
Communications biology [Commun Biol] 2021 Jan 25; Vol. 4 (1), pp. 112. Date of Electronic Publication: 2021 Jan 25.
Autor:
Borodovsky A; Discovery Biology, Nurix Inc, San Francisco, California, USA., Barbon CM; Preclinical Biology, Bluefin Biomedicine, Beverly, Massachusetts, USA., Wang Y; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Ye M; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Prickett L; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Chandra D; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Shaw J; Discovery Sciences, AstraZeneca PLC, Cambridge, Cambridgeshire, UK., Deng N; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Sachsenmeier K; Translational Medicine, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Clarke JD; Drug Metabolism and Pharamcokinetics, AstraZeneca, Cambridge, Cambridgeshire, UK., Linghu B; Translational Medicine, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Brown GA; Discovery, Omass Technologies Ltd, Oxford, United Kingdom., Brown J; Heptares Therapeutics, Welwyn Garden City, California, USA., Congreve M; Heptares Therapeutics, Welwyn Garden City, California, USA., Cheng RK; X-ray Crystallography, LeadXPro, Villigen, Switzerland., Dore AS; Heptares Therapeutics, Welwyn Garden City, California, USA., Hurrell E; Heptares Therapeutics, Welwyn Garden City, California, USA., Shao W; Oncology, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Woessner R; Pharmacology, Blueprint Medicines, Cambridge, Massachusetts, USA., Reimer C; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Drew L; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Fawell S; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Schuller AG; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Mele DA; Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA deanna.mele@astrazeneca.com.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Jul; Vol. 8 (2).